HomeLSTA • NASDAQ
add
Lisata Therapeutics Inc
Nakaraang pagsara
$2.03
Sakop ng araw
$1.94 - $2.05
Sakop ng taon
$1.81 - $4.20
Market cap
17.38M USD
Average na Volume
105.88K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | — | — |
Gastos sa pagpapatakbo | 4.41M | -17.28% |
Net na kita | -4.25M | 13.81% |
Net profit margin | — | — |
Kita sa bawat share | -0.49 | 16.95% |
EBITDA | -4.37M | 17.45% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 19.00M | -47.02% |
Kabuuang asset | 21.76M | -43.04% |
Kabuuang sagutin | 4.64M | -2.58% |
Kabuuang equity | 17.12M | — |
Natitirang share | 8.82M | — |
Presyo para makapag-book | 1.03 | — |
Return on assets | -47.04% | — |
Return on capital | -58.17% | — |
Cash Flow
Net change in cash
| (USD) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -4.25M | 13.81% |
Cash mula sa mga operasyon | -3.34M | -32.72% |
Cash mula sa pag-invest | 5.15M | 181.68% |
Cash mula sa financing | 353.00K | — |
Net change in cash | 2.16M | 124.62% |
Malayang cash flow | -1.84M | -115.02% |
Tungkol
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
Itinatag
1980
Headquarters
Website
Mga Empleyado
26
